Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer

Radiotherapy and Oncology

Volumn 97, Issue 2, 2010, Pages 200-204

  Matsuo, Yukinori ^a   Nakamoto, Yuji ^a   Nagata, Yasushi ^b   Shibuya, Keiko ^a   Takayama, Kenji ^a   Norihisa, Yoshiki ^a   Narabayashi, Masaru ^a   Mizowaki, Takashi ^a   Saga, Tsuneo ^c   Higashi, Tatsuya ^d   Togashi, Kaori ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d Shiga Medical Center Research Institute   (Japan)

Author keywords

FDG PET; Lung cancer; Stereotactic body radiation therapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RATING SCALE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 78149362217     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.04.011     Document Type: Article

References (21)

1. H. Blomgren, I. Lax, I. Näslund, and R. Svanström Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients Acta Oncol 34 1995 861 870
2. M. Uematsu, A. Shioda, and K. Tahara Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience Cancer 82 1998 1062 1070
3. Y. Matsuo, K. Shibuya, and Y. Nagata Prognostic factors in stereotactic body radiation therapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2010 10.1016/j.ijrobp.2009.12.022
4. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
5. M. Hoyer, H. Roed, and A.T. Hansen Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer Int J Radiat Oncol Biol Phys 66 2006 S128 S135
6. F.B. Zimmermann, H. Geinitz, and S. Schill Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC) Acta Oncol 45 2006 796 801
7. M. Koto, Y. Takai, and Y. Ogawa A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer Radiother Oncol 85 2007 429 434 (Pubitemid 350213143)
8. J. Bradley Radiographic response and clinical toxicity following SBRT for stage I lung cancer J Thorac Oncol 2 2007 S118 S124
9. Y. Matsuo, Y. Nagata, and T. Mizowaki Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors Int J Clin Oncol 12 2007 356 362 (Pubitemid 47573413)
10. A. Takeda, E. Kunieda, and T. Takeda Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer Int J Radiat Oncol Biol Phys 70 2008 1057 1065
11. H.I. Libshitz, and L.S. Shuman Radiation-induced pulmonary change: CT findings J Comput Assist Tomogr 8 1984 15 19
12. G.A. Silvestri, M.K. Gould, and M.L. Margolis Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition) Chest 132 2007 178S 201S
13. M.E. Juweid, and B.D. Cheson Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 2006 496 507
14. T. Berghmans, M. Dusart, and M. Paesmans Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project J Thorac Oncol 3 2008 6 12
15. A. Frank, D. Lefkowitz, and S. Jaeger Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings Int J Radiat Oncol Biol Phys 32 1995 1495 1512
16. T. Bury, J.L. Corhay, and B. Duysinx Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer Eur Respir J 14 1999 1376 1380
17. T. Inoue, E.E. Kim, and R. Komaki Detecting recurrent or residual lung cancer with FDG-PET J Nucl Med 36 1995 788 793
18. J. van Loon, J. Grutters, and R. Wanders Follow-up with (18)FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study Eur J Cancer 45 2008 588 595
19. 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy Ann Nucl Med 18 2004 669 674
20. D.J. Hoopes, M. Tann, and J.W. Fletcher FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer Lung Cancer 56 2007 229 234
21. K. Takayama, Y. Nagata, and Y. Negoro Treatment planning of stereotactic radiotherapy for solitary lung tumor Int J Radiat Oncol Biol Phys 61 2005 1565 1571